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Magnetic nanoparticles (MNPs) accumulate at disease sites with the aid of magnetic 
fields; biodegradable MNPs can be designed to facilitate drug delivery, influence 
disease diagnostics, facilitate tissue regeneration and permit protein purification. 
Because of their limited toxicity, MNPs are widely used in theranostics, simultaneously 
facilitating diagnostics and therapeutics. To realize therapeutic end points, iron oxide 
nanoparticle cores (5–30 nm) are encapsulated in a biocompatible polymer shell 
with drug cargos. Although limited, the toxic potential of MNPs parallels magnetite 
composition, along with shape, size and surface chemistry. Clearance is hastened by the 
reticuloendothelial system. To surmount translational barriers, the crystal structure, 
particle surface and magnetic properties of MNPs need to be optimized. With this 
in mind, we provide a comprehensive evaluation of advancements in MNP synthesis, 




Nanomedicines are developed to improve dis-
ease diagnosis and therapeutic indices for a 
range of injuries, infectious diseases, genetic 
and immune disorders and cancers [1]. One 
way to broaden the impact of nanomedicine 
is through theranostics, a means by which 
magnetic nanoparticles (MNPs) serve to 
facilitate both therapeutic and diagnostic end 
points [2]. MNPs were developed for labeling, 
isolation and purification of cells, proteins, 
carbohydrates, antibiotics, biopolymers and 
other biomolecules. Additional applications 
include tumor hyperthermia, tissue engineer-
ing, drug delivery and disease diagnostics 
through MRI [3–8]. MNPs are 15–30 nm in 
size and possess intrinsic superparamagnetic 
properties, enabling their transport to, and 
retention at, specific body sites aided by exter-
nal magnetic fields [9]. Therapeutic MNPs 
contain iron oxide cores of <15 nm, a biocom-
patible polymer coat, and targeting ligands 
and use MRI for detection and enablement of 
disease site delivery [10–13] (Figure 1). Similar 
approaches have been described for the design 
of nanotherapeutics for the treatment of HIV 
infection [14].
MNPs need to be biocompatible, elicit 
limited toxicity and effectively accumulate 
at disease sites to be effective [15]. The iron- 
containing particles also need to dissolve and 
release their contents for clearance by the body’s 
reticuloendothelial system (RES) [16,17]. MNP 
toxicity is linked to composition, shape, size 
and surface chemistry. Manufacturing param-
eters can limit inherent toxicities [18], enabling 
a broad use in biomedical applications [19]. The 
US FDA has approved MNPs as MRI contrast 
agents [20]. When drugs are encased in the 
nanoparticles, MNPs may evaluate drug phar-
macokinetics and bio distribution. Future ther-
apeutic values of MNPs rest in drug targeting, 
hyperthermia-induced tumor destruction and 
in rapid disease diagnoses [18]. It is noteworthy 
that materials such as cobalt, which show sig-
nificant magnetic responses, are not suited for 
clinical use based on their toxicity profiles [19].
Dhirender Singh1,2, 
JoEllyn M McMillan*,2, 
Xin-Ming Liu1,2, Hemant M 
Vishwasrao3, Alexander V 
Kabanov3, Marina Sokolsky-

















Formulation design facilitates magnetic 







Formulation design Facilitates magnetic nanoparticle delivery to 
diseased cells & tissues




For reprint orders, please contact: reprints@futuremedicine.com
Nanomedicine (Epub ahead of print) future science group470
In this article, we discuss the various methods used 
to synthesize MNPs for targeted applications in diag-
nostics and therapeutics. Specific physicochemical 
and physical parameters that are important for the 
design of effective targeted delivery of MNPs are also 
reviewed.
Formulation developments & product 
synthesis
Typically, MNPs contain a coated magnetic core 




) or its oxidized forms, 
maghemite and hematite [21]. Synthesis of MNPs is 
controlled by concentration of reactants, mixing rate, 
oxidation rate and temperature and for aqueous route 
by pH [22]. The morphology of MNPs revolves around 
their nucleation, aggregation and impurities [23]. Dif-
ferent models of particle nucleation and growth have 
been reported. LaMer and co-workers developed a 
model for MNP development [24,25], which is as fol-
lows: first, monomer concentration gradually increases 
until it reaches supersaturation; second, supersaturated 
solutions of monomers undergo nucleation; third, 
nucleation ensues resulting in the formation of large 
numbers of nuclei termed ‘bursts’. A pure solution 
results in homogeneous nucleation, whereas impuri-
ties, such as dust, initiate heterogeneous nucleation. 
Nucleation continues until monomer concentration 
drops below a critical concentration; fourth, particles 
continue to grow through absorption of additional 
monomers on their surfaces. As monomer adsorption 
is not homogeneous and depends on the surface free 
energy, nanoparticulate matter of very high surface free 
energy results in particles with broad size distribution 
[26]. To control nanoparticle growth, surfactant mol-
ecules, which consist of a hydrocarbon chain attached 
to a functional end group, are used. Surfactants bind 
to particles though the functional group, thus limiting 
particle surface reactivity and further particle growth. 
In addition, hydrocarbon chains form a hydrophobic 
shell around the magnetite/maghemite core, provid-
ing stability against oxidation to formed nanoparticles 
[27–29]. Over the past 30 years, numerous synthetic 
approaches were established to obtain reliable MNPs 
with optimum size, shape, surface charge and colloi-
dal stability. These include co-precipitation, hydro-
thermal and microemulsion syntheses and thermal 
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Figure 1. Basic features of multifunctional composite magnetic nanoparticles. Magnetic nanoparticles are capable 
of targeted delivery of a therapeutic cargo (drug, genetic material and/or imaging agent) under the influence 
of an external magnetic field. The components of multifunctional composite magnetic nanoparticles include a 
biocompatible polymeric shell (biodegradable, inorganic or natural polymers) that encapsulates the magnetic core 
along with the therapeutic payload. 
PEG: Polyethylene glycol; PGA: Polyglycolide; PLA: Polylactide; PLGA: Poly(lactide-co-glycolide).
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decomposition. Each of these ‘bottom-up’ nanopar-
ticle formation techniques provides more control over 
particle size, size distribution and phase purity than 
mechanical grinding. These synthetic methods are 
summarized and compared in Table 1.
Co-precipitation
Co-precipitation is the most common technique for 
MNP manufacture. Hydrophilic magnetite/maghemite 
nanoparticles are produced by addition of alkali to an 
aqueous salt solution of Fe2+/Fe3+ at room temperature 
under an inert atmosphere [30]. The resulting particles 
require annealing, which precludes agglomeration. 
Co-precipitation performed at higher temperatures 
(50–100°C) leads to condensation of hydroxides to 
crystalline metal oxides [31]. At first magnetite particles 
are formed and, if subjected to controlled oxidation, 
are transformed into stable maghemite particles. Con-
trolled transformation of magnetite to maghemite can 
be achieved by dispersing the magnetite particles in an 
acidic medium followed by addition of Fe3+ nitrate or 
nitric acid. Maghemite particles are more stable than 
magnetite over long time periods as they are not sen-
sitive to oxidation [31,32]. Co-precipitation is a repro-
ducible and high yield synthesis method [30]; however, 
synthesis of particles with narrow size distribution still 
remains challenging [33]. Size, shape and particle com-
position is controlled by Fe2+/Fe3 ratios and pH and 
ionic strength; the latter two also impact chemical 
composition and charge at the particle surface. Particle 
size and size distributions decrease at high pH and ionic 
strength [33,34]. Passing nitrogen gas through the reac-
tion can decrease particle size and provide protection 
against oxidation [35]. Monodispersed nanoparticles 
can also be synthesized by decreasing the nucleation 
period. Another method to control the size and shape 
of the magnetic particles is ‘in situ formation’, wherein 
co-precipitation is conducted in a polymer matrix with 
cavities of a preset size and shape, which serve as a 
template for particle formation, thus reducing particle 
polydispersity [36].
Hydrothermal synthesis
Hydrothermal synthesis is conducted at a temperature 
and pressure above 200°C and 2000 psi, respectively. 
Hydrothermal MNP synthesis proceeds by hydrolysis 
and oxidation of ferrous salt or by neutralization of 
mixed metal hydroxides [37] and promotes rapid nucle-
ation and growth of smaller high quality crystals [25,38]. 
When metal salts are dissolved under ambient condi-
tions, hydrothermal synthesis can proceed at super-
critical fluid temperatures [39]. Hydrothermal synthe-
sis is associated with formation of well- crystallized 
MNPs, which in turn translates to increased satura-
tion magnetization values [40]. In hydrothermal syn-
thesis, the geometry of the nano particles is controlled 
by optimizing reaction parameters [37]. Indeed, nano-
particle size increases with prolonged reaction times 
and higher water content promotes particle aggrega-
tion [41]. Magnetite nanoparticles of narrow size dis-
tribution and high magnetic properties are synthe-




O in basic aqueous 
media at 134°C [42]. Irregular and ellipsoid magnetite 
microtubes are obtained by neutral oxidation of Fe3+ 




, whereas magnetite nanotubes and 
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 [43]. Furthermore, the hydro-
thermal technique can be utilized to synthesize mag-
netic composite particles, such as magnetite cores with 
silicon dioxide or titanium dioxide coating [44].
Microemulsion
Reverse ‘micelle’ microemulsion is another tech-
nique for MNP synthesis. Here, soluble metal salts 
(Fe2+/Fe3+) are incorporated into aqueous microdro-
plets in oil that coalesce with hydroxide (OH-)-con-
taining microdroplets to form magnetite-containing 
microdroplets. Particle size is a function of interdroplet 
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exchange and nuclei aggregation is affected by reac-
tion temperature [45,46]. MNP synthesis by microemul-
sion can be accelerated by increased temperature [47]. 
Microemulsion is a method of choice for generating 
particles of narrow size distribution and is controlled 
by modulating the levels of aqueous droplets [48]. A 
proportional relationship between microdroplet size 
and molar water to surfactant ratio serves to control 
the particle size distribution [49]. MNPs produced by 
microemulsion are <15 nm in size and show concor-
dant chemical and physical properties [35]. The major 
drawbacks of microemulsion synthesis are low yield, 
difficulty in scale-up and difficulty in removing the 
surfactants bound to the particle surface [38]. However, 
microemulsion MNP synthesis offers the opportunity 
of simultaneous nanoparticle formation and polymer-
ization of shell coats. MNPs of 80–180-nm size can be 
synthesized by inverse microemulsion polymerization, 
while lower particle size is associated with increased 
surfactants and cross-linker concentration [50].
Thermal decomposition
Thermal decomposition provides good control over 
particle parameters [51]. Particle yield is high and scal-





), which can be further oxidized to 
form maghemite. Thermal decomposition can uti-
lize iron pentacarbonyl (Fe[CO]
5









) as precursors. MNPs 
can be synthesized in the presence of organic surfac-
tants such as oleic acid and/or oleylamine. Addition 
of oleic acid was reported to decrease particle size [53]. 
Thermal decomposition of Fe(CO)
5
 generates mono-
dispersed oleic acid-coated magnetite nanoparticles 
of sizes smaller than 10 nm [51]. If thermal decompo-
sition is carried out under air instead of inert condi-
tions, maghemite particles are formed and the size 
can be specifically tuned between 3 and 17 nm [52]. 
Maghemite can also be synthesized by addition of the 
oxidizing agent trimethylamine-N-oxide [53].
Another method to tune the size of MNPs is sepa-
ration of the nucleation and growth phases [26]. Pro-
longed thermal decomposition at low temperature 
contributes mainly to the nucleation phase, creat-
ing more nuclei and promoting formation of smaller 
sized particles [25]. Decomposition at higher tempera-
ture limits the nucleation phase, therefore promoting 
particle growth. Short nucleation time can be achieved 
by injecting cold precursors into a hot mixture of sol-
vent and surfactants, therefore limiting the nucleation 
and promoting nanoparticle growth. Temperature and 
heating rates determine the size and shape of nanopar-
ticles. Crystal/particle size increases with increased 
rate of heating from 0.4˚C/min to 3.5–4˚C/min. At 
3.5–4˚C/min growth phase begins to predominate 
over nucleation and size distribution increases from 
5–7 nm to 10–13 nm. Under these conditions, particle 
size was stable over 30 min [29,54].
Particle coating & surface stability
Surface stabilization of the MNP core with polymer, 
silica, amino groups or other organic surfactants is 
required for functionality [55], as MNPs have an intrin-
sic tendency to aggregate due to their high surface 
energy and strong magnetic dipole–dipole interactions 
[56]. Moreover, electrostatic stabilization is not ade-
quate to prevent aggregation in physiological solutions 
where salts tend to neutralize a surface charge. In vivo, 
MNP aggregates can clog capillaries [25]. MNP coat-
ing is an integral component of the design of the final 
nanoparticles system, as coating imparts colloidal sta-
bility and dispersal, prevents MNP surface oxidation, 
minimizes clearance by the RES and provides surface 
chemistry for bioconjugation of targeting ligands 
and drug molecules [18,55,57]. The literature contains a 
broad range of scientific approaches that serve to mod-
ify the MNP surface to facilitate translational clinical 
applications [21,58–60].
To surmount this obstacle, aqueous dispersion of 
MNPs is obtained by surface coating with hydrophilic 
polymers, such as polyethylene glycol (PEG), poly-
ethyl eneimine (PEI), dextran and chitosan, among 
others [61–63]. To date, several approaches are available 
to coat the MNP surface with appropriate polymers, 
including in situ and postsynthesis coating [21]. How-
ever, multiple anchoring groups on a polymer can bind 
more than one particle at a time leading to aggregates.
Polyethylene glycol
One of the most widely used approaches for the prep-
aration of stable and biocompatible nano particles 
is to graft PEG onto the MNP surface, termed 
PEGylation. Because of their biocompatibility, PEGs 
are FDA-approved excipients in numerous pharma-
ceutical formulations [64–66]. Silane-coupling agents 
and other linking chemistries, such as 3-amino-
propyltrimethoxysilane, are commonly employed to 
immobilize PEG onto the MNP surface [67,68]. PEG 
layers can improve aqueous dispersity and its hydro-
philic nature provides resistance to protein adsorp-
tion and particle opsonization, reducing RES clear-
ance and thus increasing circulation time. PEG can 
be further grafted with targeting ligands to improve 
specific accumulation into tumors or other tissue sites 
of disease [69]. As an example, water-soluble magnetite 
nano particles were synthesized with monocarboxyl-
terminated PEG allowing conjugation with anticarci-
noembryonic antigen, a cancer targeting monoclonal 
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antibody [70]. Recently, magnetic hybrid nanoparticles 
were made within a poly(lactic acid-co-glycolic acid) 
(PLGA) core, stabilized by PEG and lipid [71]. Nota-
bly, blood circulation half-life of meso-2,3-dimercap-
tosuccinic acid-coated MNP was increased twofold 
when conjugated to PEG [61].
Dextran
Dextrans are a class of biocompatible and biodegrad-
able natural polysaccharides that are commonly used 
for coating MNPs. Dextrans are commonly employed 
for MNP coating because of their affinity for the iron 
oxide surface through chelation and hydrogen bond-
ing. Carboxydextran and carboxymethyldextran are 
often used for MNP coating [18] because the length of 
the dextran chain and the large number of hydroxyl 
groups provide a high degree of hydrogen bond-
ing [41]. Therefore, many FDA-approved MNPs are 
coated with dextran and its derivatives. To prevent 
desorption of the dextran, the coating can be cross-
linked using epichlorohydrin and ammonia. However, 
although cross-linking with epichlorohydrin extends 
MNP circulation half-life, the nonbiodegradability of 
epichlorohydrin precludes use of these MNPs in clini-
cal applications. As an alternative approach, covalent 
attachments to dextran on the MNP surface can be 
achieved by modifying the MNP surface with amino-
propysilane groups [63]. Because of the large number 
of hydroxyl groups, the dextran coating can be readily 
functionalized with targeting moieties and fluorescent 
probes for specific delivery to sites of disease [63,72].
Poly(lactic-co-glycolic acid)
PLGA is a FDA-approved, biodegradable polymer, 
which has been used extensively for nanomedicine 
production, drug delivery and tissue engineering [73]. 
Furthermore, drug release rates from PLGA nano-
particles can be controlled, which is of importance for 
drug delivery [74]. Oleic acid-coated MNPs were incor-
porated into a PLGA matrix by an oil-in-water emul-
sion technique to serve as a delivery vehicle. Trans-
mission electron microscopy demonstrated that MNPs 
smaller than 10 nm in size were dispersed uniformly 
throughout the PLGA matrix [51,75]. However, PLGA 
on the surface of MNPs decreased the saturation 
magnetization to approximately half of the original 
value [76].
Polyethyleneimine
PEI is a water soluble, cationic polymer that can be 
prepared in branched or linear form. Branched PEI of 
approximately 25 kDa exhibit very high transfection 
efficiency and are considered as the ‘gold standard’ 
in the field of gene delivery [77]. PEI attachment onto 
the MNP surface can be performed by in situ coating, 
postsynthesis adsorption or grafting [18]. Capitalizing 
on these properties, PEI was recently used to modify 
MNPs for successful delivery of nucleic acids [78,79], 
where MNPs provided magnetic targeting, while PEI 
condensed the genetic material. These studies also 
demonstrated that PEI-coated MNPs improved deliv-
ery of encapsulated DNA to A549 and B16-F10 tumor 
cells in the presence of an external magnetic field [79]. 
In addition to gene transfection, PEI-modified MNPs 
have been used for delivery of a malaria DNA vaccine 
[80]. On the other hand, several problems such as its 
intrinsic toxicity and low colloidal stability restrict the 
use of PEI coating [81].
Chitosan
Chitosan is a biodegradable linear cationic polysac-
charide formed by partial deacetylation of the natural 
polysaccharide chitin [46], which is extensively used 
in therapeutic applications. A two-step synthesis of 
biocompatible MNPs was developed to coat MNPs 
formed by co-precipitation with chitosan owing to the 
poor solubility of chitosan at the pH required for co-
precipitation of MNPs [18]. First, MNPs were synthe-
sized by co-precipitation of an aqueous salt solution of 
Fe2+ and Fe3+ with ammonia in the presence of a posi-
tively charged chitosan derivative. Second, an anionic 
derivative of chitosan was adsorbed onto the positively 
charged MNP, resulting in a negatively charged MNP 
[82]. The chitosan-coated MNP exhibited a very high 
saturation magnetization and formed a highly stable 
aqueous dispersion. For example, chitosan/PEG-
coated MNPs were used for gene delivery, where the 
plasmid enhanced green fluorescence protein was 
encapsulated as a reporter gene [83]. Controlled DNA 
release from the nanoparticles was observed upon 
application of a magnetic field. Since chitosan pos-
sesses both amino and hydroxyl functional groups, 
functionalization of MNPs with imaging agents, tar-
geting ligands and therapeutic agents for multimodule 
theranostic applications is possible [84].
Silica
Silica has numerous pharmaceutical applications. Sil-
ica coating of MNPs has been used to reduce oxidation 
of the magnetic core, which is a primary reason for 
loss of transverse relaxivity of the particles [78]. The 
silica shell can protect the metallic core from oxida-
tion under aqueous conditions and silanol groups 
enable reaction with alcohols to provide stability in 
nonaqueous media and provide a platform for cova-
lent linkage to numerous specific ligands [85]. Several 
methods have been reported to immobilize mesopo-
rous silica onto the MNP surface facilitating drug 
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delivery and imaging [86,87]. However, the particles 
that are generated are often hydrophobic [25]. As an 
alternative approach, a water-in-oil microemulsion-
based synthesis has been used to generate particles 
of improved aqueous dispersity [88]. In this method, 
coating of silica onto the inner core of particles is con-
trolled by micelle formation, and the aqueous domain 
is uniformly dispersed into a continuous oil phase and 
separated by a layer of surfactant. However, in situ 
microemulsion preparation generally leads to a poor 
crystalline magnetic core, limiting its applicability for 
production of clinically useful MNPs. Monodispersed 
silica-coated paramagnetic luminescent nanoparticles 
can be synthesized by microemulsion [89]. The most 
common synthetic procedures use a template, such as 
cetyltrimethylammonium bromide (CTAB), to grow 
long tubular structures upon which silica polymer-
izes to encapsulate MNP [90]. The CTAB template 
is subsequently removed by solvent extraction to 
yield MNPs with a highly ordered mesoporous silica 
coating. Mesoporous silica microspheres encapsulat-
ing a silica-coated MNP core were synthesized using 
the surfactant-template approach [90]. In these stud-
ies, magnetite particles coated with a silica layer were 
encapsulated within a mesostructured CTAB/silica 
template. Solvent extraction of CTAB yielded meso-
porous silica microspheres containing MNPs. These 
MNP microspheres exhibited high magnetization 
and had uniform mesopores with a large pore vol-
ume. The inner silica core protects the metallic core 
from leaching, the outer mesoporous silica core pro-
vides a platform for functional derivatization and the 
large accessible pores can carry therapeutic or imaging 
cargos [90]. Of importance for imaging, silica coating 
enhances encapsulated fluorescent dye by preventing 
direct interaction with the metallic core and reducing 
luminescence quenching [91–93]. Scaled-up production 
of silica-coated MNPs is possible [94].
Gold
Fabrication of core–shell iron oxide/gold (Au) MNPs 
is achievable [93,94]. Au coating stabilizes the magne-
tite core by hampering oxidation and corrosion, and 
provides desired biocompatibility of the MNP. Au 
coating can also provide a surface for conjugation of 
a chemical or biological moiety through binding to 
thiol-terminate molecules. However, the thin Au coat-
ing does not prevent MNP aggregation, and thus an 
‘ionic capping ligand’ is required during the coating 
process [2,58]. Au-coated MNPs using 4-benzylpyri-
dine as a capping agent exhibit excellent stability in 
acidic conditions [95]. Au-coated MNPs can also be 
prepared by reduction of Au3+ onto the MNP sur-
face [96]. Au-coated MNPs were prepared by reducing 
HAuCl
4
 in a chloroform solution of magnetite in the 
presence of oleylamine, which served as both a surfac-
tant and a mild reducing agent. The Au-coated MNPs 
were subsequently transferred to an aqueous solution 
of CTAB and sodium citrate for further coating by 
addition of HAuCl
4.
 Similarly, a Au layer was coated 
onto amine-coated MNPs by sonicating MNPs in an 
aqueous solution of HAuCl
4
 in the presence of sodium 
citrate [97]. Au-coated MNPs can also be functional-
ized. Novel dumbbell-like targeted Au-coated MNPs 
were synthesized to effectively deliver platin to Her2-
positive breast cancer cells [98]. Core–shell composite 
Au-coated MNPs can be capped with CTAB to reduce 
aggregation by neutralizing the layer with a positive 
surface charge and stabilizing the core–shell nanopar-
ticles. Polyacrylic acid can then be conjugated onto the 
CTAB cap using 1-ethyl-3-(3-dimethyllaminopropyl)
carbodiimide as a cross-linker and the carboxylic 
group of polyacrylic acid can be used for conjugation 
of targeting moieties [99].
Surface functionalization
Targeted drug/gene delivery, which is achieved by 
targeting specific cell receptors, is key to reducing 
drug doses, improving drug efficacy and reducing 
unwanted toxicities [100]. In order to achieve this, 
MNP surface functionalization is critical [2]. As pre-
viously discussed, a protective coating can bestow 
physical and chemical colloidal stability and can also 
provide a platform for functionalization with specific 
targeting moieties [100,101]. Certain coatings such as Au 
and silica are excellent platforms for functionalization 
with targeting moieties due to their surface chemistry 
[55]. Numerous strategies have been utilized for tailor-
ing the MNP surface to yield biocomposite nanopar-
ticles with designated features required for biomedical 
applications [55]. The MNP surface can be function-
alized with biological ligands by either covalent cou-
pling via ester or amide linkages or by noncovalent 
grafting [21]. For covalent bonding, functional moi-
eties are attached to the MNP surface using various 
linkers such as 1-ethyl-3-(3-dimethyllaminopropyl)
carbodiimide/N-hydroxysuccinimide, maleimide, 
pyridyl disulfide, or N-succinimidyl 3-(2-pyridyldi-
thio) propionate [20]. Carbodiimide cross-linker chem-
istry is used for conjugation of a peptide or other moi-
ety to the hydrophobic MNP surface via formation 
of an amide bond [58]. Biological ligands can be non-
covalently grafted to MNPs through ionic bonding, 
physical adsorption or streptavidin conjugation [102]. 
Ionic bonding can be manipulated chemically or by 
adjusting the ionic strength and/or pH of the solution. 
Although, non covalent grafting of biomolecules offers 
a relatively easy approach, the bond can be unstable 
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under physiological conditions, leading to detach-
ment of the coating and precipitation of the MNP. 
Moreover, results of noncovalent grafting are often 
not reproducible and may produce erratic biological 
responses. To overcome these shortcomings, develop-
ment of stable covalent linkages resistant to oxidation, 
hydrolysis and reducing conditions has gained more 
attention. However, a key concern during fabrication 
of functionalized biomagnetic nanoparticles is to pre-
serve the activity and properties of the bioactive func-
tional groups. Use of small molecules, in addition to 
increasing affinity through multivalent attachments, 
offers an advantage to preserving the functionality 
throughout synthesis [103]. By contrast, large mole-
cules, such as proteins and antibodies, often lose func-
tionality during the conjugation step. Conjugation of 
monoclonal antibodies to the MNP surface usually 
involves covalent binding of the most reactive amino 
groups present at the antigen-binding site (i.e., Fab). 
Furthermore, attachment may lead to random orien-
tation of the antibodies, compromising their immune 
reactivity [104]. Several strategies have been employed 
to attach antibodies oriented in such a manner so as to 
maintain functionality, including use of immobilized 
protein [105] and immobilization through the sugar 
chain of the antibodies [106]. These approaches immo-
bilize antibody onto the MNP surface through the Fc 
region, leaving the Fab region available for molecular 
recognition. A two-step approach for the attachment 
of antibody without loss of orientation was described 
[107]. The antibody is first adsorbed to the surface of 
the MNP via ionic adsorption, followed by an irrevers-
ible covalent attachment. Surface functionalization 
using antibodies has limitations that include insta-
bility with the polymeric coat, particle aggregation 
with small fluctuations in ionic strength and/or pH, 
and unequal distribution over the MNP surface [107]. 
Moreover, conjugation of antibodies onto the MNP 
surface is usually a complex process due to the large 
size of the antibody, which impedes particle extrava-
sation. Complicating matters, monoclonal antibod-
ies are immunogenic in nature and can thus elicit an 
immune response that limits repeated application of 
the carrier system. Nevertheless, functionalization 
of MNPs with large proteins and antibodies is being 
explored for a variety of therapeutic applications. Liu 
et al. covalently attached antitumor antibody onto 
PEGylated MNPs using a ‘click reaction’ [108]. Others 
demonstrated good targeting efficiency of PEGylated 
MNPs functionalized with a monoclonal antibody to 
lymphatic vessel endothelial hyaluronan receptor-1 to 
mouse lymphatic endothelial cells [109]. In addition, 
accumulation of MNPs conjugated with luteinizing 
hormone-releasing hormone at the site of tumors that 
overexpress luteinizing hormone- releasing hormone 
receptors was demonstrated in breast and metastatic 
lung cancers, supporting the clinical applications of 
these particles [110].
The folate receptor binds folate and its conjugates 
with high affinity and is a common target for the 
management of various types of human cancers [111]. 
Folic acid-conjugated MNPs are a classic example of 
targeted delivery using MNPs. Folic acid-conjugated 
MNPs were used to target human nasopharyngeal epi-
dermal carcinoma [72], breast cancer [112] and human 
hepatic carcinoma [113]. Multifunctional MNPs were 
produced where core–shell biodegradable magnetite 
nanospheres were conjugated to doxorubicin through 
a carboxyl linkage and functionalized with iminodi-
acetic acid-modified folate to provide tumor-targeting 
capability [114]. Other multifunctional MNPs have also 
been developed for targeted delivery of doxorubicin 
[115]. MNPs were coated with dual-responsive poly(N-
isopropylacrylamide)-block-poly(acrylic acid) block 
copolymer, which enabled the sustained release of 
encapsulated doxorubicin at a desired temperature and 
low lysosomal pH. Cancer cell targeting was imparted 
to the design by tethering folic acid onto the surface of 
the MNP through an amide linkage.
Peptides can also be conjugated onto the surface of 
MNPs as functional moieties. The most commonly 
used peptide is arginine–glycine–aspartate, the recog-




 receptor, which is over-
expressed in tumor blood vessels and some melanoma 
cancers [116]. Carboxymethyl dextran-coated ultrasmall 
MNPs conjugated with cyclic arginine–glycine–aspar-
tate peptides exhibited higher uptake by Bcap37 cells 
compared with nontargeted MNPs [117]. In other stud-
ies, MNPs functionalized with a peptide targeted to the 
urokinase plasminogen activator receptor demonstrated 
fivefold greater uptake by urokinase plasminogen acti-
vator receptor-positive cells compared with untargeted 
MNPs [12]. Tumor-targeting capability of a magnetic 
nanovector consisting of a MNP core coated with co-
polymers of chitosan, PEG and PEI and conjugated 
with chlorotoxin was demonstrated by preferential 
accumulation in glioma cells in mice bearing C6 xeno-
graft tumors [118]. In a unique application, MNPs func-
tionalized with material-specific peptides were used 
to purify metals of interest from a colloidal mixture 
using an external magnetic field [119]. Thus, streptavi-
din-coated MNPs were modified with an Au-specific 
peptide to sequester Au nanoparticles from a colloidal 
mixture of Au and cadmium sulfide nanoparticles.
Conjugation of adenoviral vectors onto MNPs can 
provide concurrent MRI and gene delivery applica-
tions [55]. While adenoviral vectors offer the potential 
for vascular gene therapy, their rapid inactivation, 
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suboptimal transduction efficiency and inherent 
immunogenicity, limit their applicability. The polymer 
coating of MNPs can protect the conjugated adeno-
virus from inactivation, and transfection efficiency can 
be enhanced by application of an external magnetic 
field to target the MNP to the desired site of action 
[120,121]. This was demonstrated in studies where suc-
cessful transduction of endothelial and smooth muscle 
cells by adenovirus-conjugated MNPs occurred even 
after exposure to adenovirus-neutralizing anti bodies 
and lithium iodide, an adenovirus disrupter agent 
[122]. Adenovirus-conjugated magnetic beads, under 
an external magnetic field, successfully transduced 
adenoviral vectors encoded with the hVEGF gene for 
regeneration of ischemically damaged hearts in an 
acute myocardial infarction rat model [123]. Fabrication 
of biocomposite MNPs has also been described using 
other biomolecules such as bovine serum albumin [124], 
TAT peptide [125] and transferrin [126], each designed 
to impart a specific targeting efficacy to the particles.
Design considerations
The physicochemical characteristics of MNPs are of 
importance when designing a successful drug delivery 
system. Surface coating and functionalization of MNPs 
can be tailored to particular biomedical applications. 
Moreover, a biocomposite nanoconstruct requires that 
the biomolecule is biocompatible with biological sys-
tems and is not associated with any adverse effects. In 
addition, a biomolecule should impart adequate colloi-
dal stability to allow the biocomposite MNP to reach 
its target [25,37,55]. A key fundamental consideration for 
synthesis of successful MNPs is discussed below.
Geometry
Size and shape are the key physical parameters that 
govern not only the colloidal stability of MNPs, but 
also influence the magnetic moment of the particles, 
and therefore the response to an external magnetic field 
[55]. For instance, saturation magnetization of MNPs is 
known to decrease with a decrease in particle size, a 
consequence of increased surface area that may have an 
impact on the magnetic moment [127]. However, par-
ticles smaller than 2 nm in size can diffuse through the 
cell membrane and damage intracellular organelles, 
and are thus not suitable for biomedical applications. 
The blood half-life of MNPs is determined in part by 
particle size. Particles smaller than 20 nm in size are 
excreted via the kidney, while particles greater than 
200 nm in size accumulate in the spleen and the liver 
and are cleared from the circulation by tissue-resident 
macrophages [128]. Particles 10–200 nm in size exhibit 
longer circulation time by avoiding sequestration by 
the RES and are thus considered optimum for biomed-
ical applications [129]. Smaller spherical nano particles 
concentrate at the center of blood vessels due to their 
higher diffusion rate, which restricts their interac-
tion with endothelial cells and extends blood circula-
tion time [18]. Moreover, nanoparticles of sizes smaller 
than 200 nm that avoid opsonization and RES uptake 
accumulate at a tumor site because of the enhanced 
permeation and retention effect [130,131]. Another key 
parameter that governs the biodistribution of MNPs 
is particle shape. Particle shape can influence the 
biodistribution and clearance of nanoparticles [132]. 
Huang et al. observed that rod-shaped and nonspheri-
cal nanoparticles showed prolonged systemic circula-
tion compared with spherical nanoparticles. Moreover, 
they found that short rod-shaped mesoporous silica 
nanoparticles accumulated in the liver, whereas long 
rod-shaped nanoparticles accumulated in the spleen. 
Additionally, in contrast to long rod-shaped particles, 
short rod-shaped mesoporous silica nanoparticles were 
rapidly cleared from the circulation. These studies 
demonstrated that spherical nanoparticles are engulfed 
by phagocytic cells to a greater extent than nonspheri-
cal or rod-shaped nanoparticles in support of the lon-
ger circulation half-lives of nonspherical or rod-shaped 
nanoparticles. Moreover, shape directly influences cel-
lular entry of nanoparticles. For instance, rod-shaped 
nanoparticles larger than 100 nm exhibit the highest 
cellular uptake, followed by spherical-, cylindrical- and 
cuboidal-shaped nanoparticles of similar sizes. How-
ever, for particle sizes smaller than 100 nm, spherical 
nanoparticles exhibit preferentially higher cell uptake 
over rod-shaped nanoparticles [56].
Surface charge
Surface charge on MNPs is measured as the electro-
static potential at the surface of nanoparticles, termed 
‘zeta potential’ or ‘electrokinetic potential’. Zeta 
potential can indicate attachment of drug molecules 
onto the MNP surface and is a function of charge sta-
tus of the drug moiety. It has been well established that 
the surface charge of MNPs determines the colloidal 
stability and influences biodistribution of nanoparti-
cles. Following intravenous injection, MNPs encoun-
ter physiological conditions of higher ionic strength 
and a slightly basic pH (pH 7.4). These unfavorable 
conditions, in combination with the inherent mag-
netic attraction of MNPs, induce particle aggrega-
tion. The hydrophobic and charged MNP surface 
undergoes nonspecific association with plasma pro-
teins (i.e., opsonin) and extracellular matrix leading 
to RES clearance. These effects are counteracted by 
electrostatic repulsion induced by a charged particle 
surface, grafting a hydrophilic coating onto the par-
ticles and by coating the particles with a protective 
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shell (steric barrier) [37,130]. The charge status of MNPs 
also impacts cellular internalization, thus influencing 
biodistribution. Positively charged nanoparticles show 
a higher rate of cellular uptake in comparison with 
negatively charged or neutral nanoparticles. As a con-
sequence, positively charged nanoparticles have a rela-
tively shorter blood half-life than negatively charged 
or neutral particles [133]. Positively charged MNPs are 
internalized by human breast cancer cells with higher 
efficiency compared with negatively charged MNPs. 
However, the uptake of MNPs can be cell type-spe-
cific as demonstrated by the lack of differential inter-
nalization of these particles by human umbilical vein 
endothelial cells [134].
Nonspecific adsorption of plasma proteins leads 
to clearance by the RES and is a function of the sur-
face properties of nanoparticles including size, charge 
and hydrophilicity/hydrophobicity. Opsonization is 
greatly reduced for hydrophilic particles of small size 
[135]. To limit nanoparticle clearance by the RES, 
‘stealth’ nanoparticles have been developed by coating 
the particles with PEG. PEGylation decreases particle 
interaction with the RES by reducing the potential for 
opsonization through steric hindrance [66]. Lee et al. 
reported that by using poly(3-[trimethoxysilyl propyl]
methacrylate-r-polyethyleneglycol methacrylate) con-
sisting of a surface anchoring moiety (silane group) 
and a “protein-resistant moiety” (PEG), to coat the 
magnetic core, protein- and cell- resistant MNP could 
be generated [59] that showed an extended circulation 
half-life.
Surface thermodynamics & colloidal stability
Colloidal stability of MNPs in an aqueous solution 
is a prerequisite for biomedical applications. Inter-
particle interactions and wettability of particles in 
aqueous media govern the interfacial surface energy, 
which impacts particle aggregation and polydisper-
sity. Moreover, the thermodynamic stability of MNPs 
in the absence of a magnetic field depends upon the 
balance between electrostatic forces, such as attrac-
tive forces (dipole–dipole and van der Waal interac-
tions) and repulsive forces (steric and electrostatic). 
Electrostatic interaction can be adjusted by altering 
reaction parameters such as ionic strength and pH. 
In an aqueous solution, hydrophobic MNPs tend to 
aggregate due to hydrophobic attraction. Therefore, 
grafting a hydrophilic moiety such as PEG onto the 
particle surface can provide adequate aqueous thermo-
dynamic stability. Hydrophobic aggregation of MNPs 
is usually marked by a negative surface free energy, 
whereas making the MNP surface more hydrophilic 
through engraftment of a hydrophilic moiety is asso-
ciated with positive free energy, which supports par-
ticle dispersion and adequate aqueous stability. The 
moderate density of MNPs also supports resistance 
against gravitational settling in low blood flow [37,136]. 
Opsonization is influenced by the hydrophilic/hydro-
phobic nature of MNPs and occurs more rapidly with 
hydrophobic particles [137]. Adequate colloidal stability 
can thus be conferred by adsorption and/or grafting of 
surface stabilizers (e.g., PEG) onto the MNP surface. 
A sufficient stabilizer coating surrounding the MNP 
core can provide steric stabilization to overcome mag-
netic potentials and van der Waals attractive forces to 
impart long-term colloidal stability, even under harsh 
electrolyte, temperature and pH conditions [15,101,138].
The colloidal stability of MNPs can be monitored 
by periodic measurements of size as a function of elec-
trolyte concentration and/or pH during a defined time 
period [139]. Aggregation of the particles can be deter-
mined by appearance of particles with larger hydro-
dynamic size. Moreover, long-term colloidal stability 
of MNPs under physiological conditions can be deter-
mined from temperature-dependent measurements of 
particle size using dynamic light scattering, which can 
provide a good estimation of the reversibility and bind-
ing affinity of the stabilizer coating on the MNP sur-
face [140]. The colloidal stability of MNPs in solution 
can also be determined by analyzing the aggregation 
kinetics of MNPs using turbidity measurements [141].
Drug encapsulation
MNPs encapsulated with therapeutic cargo are effi-
cient drug delivery vehicles, providing stabilization 
of the drug in physiological conditions, flexible drug 
loading and controlled drug release at the target site, 
while limiting nonspecific interactions with cells and 
other plasma proteins (Figure 2) [142–144]. The design 
of drug-loaded MNPs must consider all these factors. 
Of primary importance in constructing drug-loaded 
MNPs is that drug function should not be compro-
mised during the loading process. Moreover, the drug-
loaded MNPs should encapsulate and protect a signifi-
cant amount of therapeutic cargo, as determined by 
the method of drug loading and the nature of particle 
coating. Finally, drug-loaded MNPs should release 
their cargo in a controlled manner at the designated 
site for optimal efficacy. For instance, release of gene 
therapy cargo from MNPs can be tailored to respond 
to the cell cycle for optimal transfection [18].
Encapsulation of a drug onto MNPs can be achieved 
either by conjugation of the drug onto the surface via 
a physical or chemical linkage [145] or by encapsulat-
ing the drug into a composite polymer matrix [51]. A 
number of approaches have been utilized to encap-
sulate and/or conjugate drug or functional-targeting 
ligands onto the MNP surface, including conjugation 
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using cleavable covalent linkage and physical adsorp-
tion for intracellular release. Drug molecules are usu-
ally conjugated to the MNP surface through functional 
groups, such as thiol, hydroxyl and amino groups, on 
the polymer used to coat MNP, or conjugated to the 
MNP using cross-linkers, such as maleimide, and 
bifunctional cross-linkers, such as pyridyl disulfide 
[51,145,146]. Covalent linkage encapsulates the drug with 
high efficiency, while protecting the functionality and 
efficacy of the drug molecule. For encapsulation of 
peptides and proteins, which are susceptible to degra-
dation under harsh oxidative conditions, milder con-
jugation reaction conditions need to be used. In some 
instances, however, a stable covalent linkage between 
the drug and the MNP can result in failure of drug 
release at the target site [146].
Drug molecules can be physically adsorbed onto 
the surface of MNP via electrostatic and affinity 
interactions [147]. This technique has been especially 
useful for encapsulation of nucleic acids. As an exam-
ple, MNPs coated with a cationic lipid interlayer and 
coupled with negatively charged plasmid DNA via 
electrostatic interaction successfully delivered nucleic 
acids to a target site using magnetic transfection 
[147]. Similarly, MNPs coated within PEI, a cationic 
polymer, successfully condensed negatively charged 
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Figure 2. Cellular uptake of magnetic nanoparticles and intracellular release of therapeutic cargo under the 
influence of an applied magnetic field. Composite MNPs are shown with their ability to deliver a therapeutic 
payload to cells under the guidance of an external magnetic field. MNPs can be engineered with targeting 
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genetic material and improved the transfection effi-
ciency of the carrier system under the influence of an 
external magnetic field [79]. Hydrophobic drugs can 
also be encapsulated via hydrophobic interactions. 
Thus, MNPs coated with a hydrophobic polymer 
matrix can encapsulate drugs by hydrophobic interac-
tion and then release the loaded drugs upon degrada-
tion of the polymer shell [146]. Affinity interactions, 
such as streptavidin–biotin bioconjugation, are also 
employed to couple the drug molecules or target-
ing ligands with MNPs. Contrary to hydrophobic 
and electrostatic interaction, affinity interaction is 
a stable noncovalent linkage that provides improved 
stability in a variety of electrolyte and pH conditions 
[148]. The downside of physical conjugation of drugs 
onto the MNP surface is poor drug entrapment effi-
ciency [146]. To overcome low entrapment efficiency, 
drug molecules can be encapsulated into the polymer 
matrix along with MNPs [51,149]. Moreover, magneto-
liposomes, which represent a novel class of magnetic 
composite nanoconstructs, offer a platform to ensure 
higher entrapment of both MNPs and drug molecules, 
while providing an optimum magnetic response and 
maintaining therapeutic efficacy of the encapsulated 
cargo [150,151].
Magnetism
Several excellent reviews have been published to 
elaborate on the magnetic characteristics of MNPs 
[2,25,37,55,152]. In the present article, we will limit 
our discussion to a brief overview of the superpara-
magnetic behavior of MNPs. Superparamagnetism 
is required for MNPs to be useful for biomedical 
applications [153]. Superparamagnetism is a type of 
magnetism, which occurs in <50 nm, single-domain 
nanoparticles, where the total magnetic moment of 
the nanoparticle is a summary of magnetic moments 
of all the atoms comprising the nanoparticle [153].
The magnetic property of any material is described 
by the significance of correlation between magnetic 
induction (B) and magnetic field (H) [37,153,154]. In 
most MNPs, the dependence of magnetic induction 
on the magnetic field can be best described by a linear 
relationship between B and H; B = μH, where μ is the 
magnetic permeability of the MNP. A MNP exhibits 
paramagnetism in the case of μ > 1, and diamagne-
tism in the case of μ < 1. Alternatively, magnetic sus-
ceptibility (χ = μ-1) can be used to describe magne-
tism in MNPs; for paramagnetic MNPs χ > 0, and for 
diamagnetic particles χ < 0 [37,58]. Ferromagnetic par-
ticles, which usually have an unpaired electron spin, 
exhibit permanent magnetization in the absence of an 
external magnetic field. However, once ground down 
to a dimension <30 nm, particles become single-
domain particles and become superparamagnetic. For 
superparamagnetic nanoparticles, no permanent mag-
netism remains upon suppression of an external mag-
netic field, which reduces aggregation, extends blood 
circulation half-life and avoids formation of embo-
lisms in blood vessels. However, although there is an 
increase in superparamagnetic behaviors with reduc-
tion in size, saturation magnetism of MNPs decreases 
with particle sizes <10 nm, and this adversely affects 
the susceptibility of the particle to magnetic target-
ing, as well as the relaxivity and thus efficiency of 
MNPs for biomedical applications. Decreased particle 
size has a significant impact on surface effects such 
as spin-canting, noncollinear spin and spin-glass-like 
behavior, which results in an alteration of magnetic 
properties. Moreover, MNPs obtained from different 
synthetic procedures display significant variations in 
their magnetic properties, such as saturation mag-
netization. These differences have been attributed 
to the crystal structure, impurities and surface coat-
ing. Superparamagnetic MNPs, in addition to their 
desired magnetic properties, also offer an advantage of 
heating behavior that comes from the Neel relaxation 
mechanism, which is widely employed in the field of 
hyperthermia [37,154].
Conclusion & future perspective
Recent medical research suggests that MNP-based 
biocomposites can be a promising platform for 
numerous in vitro and in vivo biological applications. 
The versatility of MNP-based nanotechnology is 
attributed to their capability to respond to an exter-
nal magnetic force, and in most cases, their inherent 
ability to be functionalized with bioactive moieties. 
To date, MNPs are widely accepted for human use as 
MRI contrast agents, with formulations such as Feri-
dex IV®, Endorem®, Combidex®, Lumiren® (all from 
Advanced Magnetic [155–157].
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